

The prevalence of cryptococcal antigen (CrAg) and benefits of pre-emptive antifungal treatment among HIV-infected persons with CD4+ T-cell counts < 200 cells/ μ L: Evidence based on a meta-analysis

Yao Li

Chongqing Public Health Medical Center <https://orcid.org/0000-0003-4330-6440>

Xiaojie Huang

Beijing You' an Hospital

Hui Chen

Beijing You' an Hospital

Yuanyuan Qin

Chongqing Public Health Medical Center

Jianhua Hou

Beijing You' an Hospital

Aixin Li

Beijing You' an Hospital

Hao Wu

Beijing You' an Hospital

Xiaofeng Yan

Chongqing Public Health Medical Center

Yaokai Chen (✉ yaokaichen@hotmail.com)

Review

Keywords: HIV, cryptococcal antigenemia, screening, CD4+T cell count, pre-emptive treatment, meta-analysis

Posted Date: April 2nd, 2020

DOI: <https://doi.org/10.21203/rs.2.14337/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at BMC Infectious Diseases on June 12th, 2020. See the published version at <https://doi.org/10.1186/s12879-020-05126-z>.

Abstract

Background: Current WHO guidelines (2018) recommend screening for cryptococcal antigen (CrAg) in HIV-infected persons with CD4<100 cells/ μ L, followed by pre-emptive antifungal therapy among CrAg positive (CrAg+) persons, to prevent Cryptococcal meningitis related deaths. The strategy may also be considered for those persons with a CD4 count of <200 cells/ μ L according to the WHO guidelines. However, there remains little evidence for doing so in those HIV-infected persons with this CD4 cell count. **Objective:** We aimed to assess the necessity of CrAg screening and the efficacy of pre-emptive antifungal therapy in CrAg+ persons with CD4<200 cells/ μ L. **Methods:** We conducted a meta-analysis using data obtained from randomized controlled studies (RCTs) and cohort studies found in Pubmed, Web of Science, Cochrane Library and EMBASE/MEDLINE. **Results:** The pooled prevalence of CrAg positivity in HIV-infected persons with CD4<200 cells/ μ L was 5% (95%CI: 3-6). The incidence of CM in CrAg+ persons was 7-fold (7%, 95%CI: 4-10) that of CrAg negative (CrAg-) persons (1%, 95%CI: 0-1). Among CrAg+ persons who did not receive any treatment or only received placebo, the incidence of CM was 9% (95%CI: 5-13), whereas the incidence of CM among those who received antifungal therapy was 2% (95%CI: 0-3), a highly statistically significant reduction of 78% (RR: 6.03, 95%CI: 2.74-13.24, $p < 0.00001$). **Conclusions:** In our meta-analysis, the incidence of CM in CrAg+ persons were significantly higher than in CrAg- persons with CD4<200 cells/ μ L. Furthermore, the incidence of CM was significantly reduced by pre-emptive antifungal therapy in CrAg+ persons with CD4<200 cells/ μ L.

Introduction

Cryptococcal meningitis (CM) continues to cause significant mortality in HIV-infected individuals (1, 2), and results in 181100 deaths globally each year (3). In resource-limited regions such as sub-Saharan Africa, 15% of HIV-related deaths are due to CM (3). However, it is possible to detect cryptococcal antigen (CrAg) in blood several weeks to months (22 days on average) before the onset of signs and symptoms of meningitis (4, 5), and thus, the presence of CrAg in blood may be used as a marker for initiation of pre-emptive antifungal therapy in HIV-infected individuals with low CD4+ T cell counts. Previous studies have emphasized that pre-emptive antifungal therapy in CrAg+ persons is imperative to prevent death (6-8). The prevalence of CrAg positivity among HIV-infected individuals can be considerable, ranging between 1% to 16% in several African and Southeast Asian countries (9), and among persons with CD4+ T cell counts<100 cells/ μ L, the prevalence of CrAg positivity averages 7%, with regional variations in prevalence (3). CrAg positivity resulted in a 20% increase in mortality after antiretroviral therapy (ART) initiation (10) if fluconazole therapy was not initiated prior to ART initiation, and the risk of CM in CrAg+ persons may be as high as 25% during the first year of ART, when fluconazole pre-emptive therapy is not prescribed for these patients (11, 12).

According to the 2018 version of the WHO guidelines, routine CrAg screening and pre-emptive antifungal therapy are recommended in treatment-naive HIV persons with CD4+ T cell counts<100 cells/ μ L (13). The guidelines also state that these strategies may also be considered for HIV-infected persons with CD4+ T cell counts<200 cells/ μ L (13). We therefore conducted a meta-analysis to investigate the prevalence of CrAg positivity in HIV-infected patients, and the benefit of pre-emptive antifungal treatment in HIV-infected persons with CD4+ T cell counts<200 cells/ μ L.

Method

Search strategy and article screening

We searched relevant English articles in Pubmed, Cochrane Library, MEDLINE/EMBASE and Web of Science from inception until the end of March 20th 2020. The search terms we used were as follows: "acquired immunodeficiency syndrome", "HIV", "AIDS", "cryptococcosis", and "prophylaxis". We combined these terms by using "and" or "or". To avoid missing significant articles, we also screened references of previous meta-analyses and their included studies for eligibility.

Two reviewers (Y L, Y Q) independently screened all obtained articles by titles and abstracts. After removing ineligible articles by referring to our inclusion and exclusion criteria, the remaining articles were further selected for full-text reviewing.

Inclusion and exclusion criteria

Inclusion criteria

Randomized-controlled studies (RCTs) or cohort studies were included with the following criteria:

1. Study subjects had baseline CD4+ T cell counts<200 cells/ μ L.
2. CrAg serology was tested for study subjects.
3. Fluconazole or other azole medications were used as the intervention.

Exclusion criteria

We excluded articles if: (1) all of the study subjects were diagnosed with CM or asymptomatic CM; (2) sample size was less than 50; or (3) the incidence of CM and all-cause mortality was unreported.

Data extraction and quality assessment

The data we extracted included first author, publication year, type of study, study duration, study location, total number of study subjects, baseline CD4+ T-cell counts, age, CrAg screening methods, diagnostic methods for CM, CM events, death events, adverse drug effects, and other opportunistic infections. The JBI (Joanna Briggs Institute) Critical Appraisal Checklist for Cohort Studies was used as a quality assessment tool for cohort studies (14). The potential bias risk of RCTs was assessed using the Cochrane "risk of bias" tool (15).

Data analysis

Statistical analysis of data related to proportion of CrAg positivity, the incidence of CM, and all-cause mortality were performed by STATA 14 (Statacorp, Texas, USA) with a 95% confidence interval (95%CI). We used random-effects or fixed-effects models in Review manager 5.3 (The Nordic Cochrane Center, Copenhagen) to compare the incidence of CM and all-cause mortality in CrAg+ persons.

We evaluated statistical heterogeneity through visual inspection of forest plots. Statistical heterogeneity was also assessed using I^2 statistics (16), which was considered non-negligible if $I^2 > 50\%$. Herein, random-model was applied if $I^2 > 50\%$ and fixed-model was used when $I^2 < 50\%$ (17). Reporting bias was assessed by examining the asymmetry of funnel plots (16).

The study was registered at the International Prospective Register of Systematic Reviews (PROSPERO), and the registration number is CRD42018110980.

Results

In total, 517 articles were obtained from 4 databases, among which 295 were from Pubmed, 111 were from Web of Science, 13 were from Cochrane Library, and 98 were from MEDLINE/EMBASE. 84 of the 517 articles were RCTs or cohort studies. Additional 12 articles (RCTs or cohort studies) were extracted from references of previous meta-analyses and their included studies.

All the 96 RCTs or cohort studies were included for screening. Initially, nine articles (six from Web of Science and three from MEDLINE/EMBASE) were found to be duplicated, and were therefore excluded from the 96 articles. After screening titles and abstracts, 43 of the remaining 87 articles were excluded. Subsequently, 25 articles were excluded from the remaining 44 articles after screening the full-text of each study, among which one article was a news report, three articles reported patients with cryptococcal disease, two articles reported HIV-negative patients with cryptococcal antigenemia, four articles reported data from patients with CM or asymptomatic CM, six articles reported data from HIV-infected patients with negative CrAg, one article reported on the epidemiology of cryptococcosis, and eight articles did not report CD4+ T cell counts or primary outcomes. Finally, a total of 19 articles were included in our meta-analysis.

The characteristics of the 19 included studies were shown in Table 1. Our assessment of quality and potential risk bias in these studies indicated that the following factors could contribute to clinical and methodological heterogeneity, including: (1) the confounding factors or subject recruiting or incomplete follow-up in nine of the 18 cohort studies, (2) the unclear risk of attrition in the RCT, and (3) the unclear risk of reporting and other bias in the RCT, as shown in Supplementary Table 1 and Supplementary Table 2.

Fourteen of the 19 included studies reported the prevalence of CrAg positivity (1949 persons with CD4+ T cell counts < 200 cells/ μ L in four studies; 783 persons with CD4+ T cell counts < 150 cells/ μ L in one study; 5984 persons with CD4+ T cell counts < 100 cells/ μ L in nine studies). The pooled CrAg positivity prevalence in 8716 HIV-infected persons with CD4+ T cell counts < 200 cells/ μ L was 6% (95%CI: 4-7, $I^2=92.0\%$), as shown in Figure 2.

Fourteen studies reported the incidence of CM among CrAg+ persons (1806 persons with CD4+ T cell counts < 200 cells/ μ L in four studies; 312 persons with CD4+ T cell counts < 150 cells/ μ L in two study; 248 persons with CD4+ T cell counts < 100 cells/ μ L in eight studies), and five studies reported the incidence of CM among CrAg- persons (54 persons with CD4+ T cell counts < 200 cells/ μ L in one studies; 4020 persons with CD4+ T cell counts < 100 cells/ μ L in four studies). The incidence of CM in 2349 CrAg+ persons was 7% (95%CI: 4-10; $P=0.000$; $I^2=72.8\%$), whereas the incidence of CM in 4074 CrAg- persons was 0% (95%CI: 0-1; $P=0.071$; $I^2=53.6\%$), as shown in Table 2 and Supplementary Figure 1a.

Eleven studies reported the incidence of CM among persons who received antifungal therapy (922 persons with CD4+ T cell counts < 200 cells/ μ L in four studies; 166 persons with CD4+ T cell counts < 150 cells/ μ L in two studies; 240 persons with CD4+ T cell counts < 100 cells/ μ L in five studies), and nine studies reported the incidence of CM among persons who received placebo or no intervention (946 persons with CD4+ T cell counts < 200 cells/ μ L in three studies; 146 persons with CD4+ T cell counts < 150 cells/ μ L in one study; 160 persons with CD4+ T cell counts < 100 cells/ μ L in five studies). The incidence of CM of 1163 persons receiving antifungal therapy was 3% (95%CI: 1-5; $P=0.000$; $I^2=70.5\%$), whereas the incidence of CM of 1252 persons in nine studies who received placebo or no intervention was 9%, which equates to a 67% reduction in CM incidence in persons receiving antifungal therapy (95%CI: 5-13; $P=0.000$; $I^2=73.7\%$), as shown in Table 2 and Supplementary Figure 1b.

Five studies compared the incidence of CM between 1094 persons receiving azoles and 1076 persons receiving placebo or no intervention (1785 persons with CD4+ T cell counts < 200 cells/ μ L in three studies; 295 persons with CD4+ T cell counts < 150 cells/ μ L in one study; 90 persons with CD4+ T cell counts < 100 cells/ μ L in one study). We found that the risk ratio of CM events among persons who received placebo or no intervention was 5.51 times higher than that of those who received antifungal therapy (95%CI: 2.60-11.67; $P<0.00001$; $I^2=15\%$), as shown in Figure 3.

Fourteen studies reported all-cause mortality among CrAg+ persons (1953 persons with CD4+ T cell counts < 200 cells/ μ L in six studies; 312 persons with CD < 150 cells/ μ L in two studies; 255 persons with CD4+ T cell counts < 100 cells/ μ L in six studies), seven studies reported all-cause mortality in CrAg- persons (54 persons with CD4+ T cell counts < 200 cells/ μ L in one study; 4000 persons with CD4+ T cell counts < 100 cells/ μ L in six studies). The all-cause mortality of 2520 CrAg+ persons was 18% (95%CI: 11-25; $P=0.000$; $I^2=93.6\%$), 1.06 times that of 4054 CrAg- persons (17%, 95%CI: 7-27; $P=0.000$; $I^2=98.8\%$), as shown in Table 2 and Supplementary Figure 2a.

Ten studies reported all-cause mortality in persons who received antifungal therapy (230 persons with CD4+ T cell counts < 200 cells/ μ L in four studies; 166 persons with CD4+ T cell counts < 150 cells/ μ in two studies; 240 persons with CD4+ T cell counts < 100 cells/ μ L in four studies), seven studies reported all-cause mortality in persons receiving placebo or no intervention (946 persons with CD4+ T cell counts < 200 cells/ μ L in three studies; 146 persons with CD4+ T cell counts < 150 cells/ μ L in one study; 110 persons with CD4+ T cell counts < 100 cells/ μ L in three studies). The all-cause mortality of 636 persons receiving

antifungal therapy was 17% (95%CI: 11-22; $P=0.000$; $I^2=69.5\%$), which was similar to that of 1202 CrAg- persons receiving placebo or no intervention (16%, 95%CI: 7-24; $P=0.000$; $I^2=92.4\%$). Details are shown in Table 2 and Supplementary Figure 2b.

Five studies (1897 persons with CD4+ T cell counts <200 cells/ μ L in three studies; 295 persons with CD4+ T cell counts <150 cells/ μ L in one study; 90 persons with CD4+ T cell counts <100 cells/ μ L in one study) compared all-cause mortality between persons who received azole antifungal therapy and persons who received placebo or no intervention. No significant difference was found in all-cause mortality (risk ratio: 0.82, 95%CI: 0.42-1.60; $P=0.04$; $I^2=61\%$) between 1138 CrAg+ persons who received an azole drug and 1144 CrAg+ persons who received placebo or no intervention (Figure 4).

In addition, we estimated and compared the prevalence of CrAg positivity, the incidence of CM and all-cause mortality between persons with CD4+ T cell counts <100 and persons with CD4+ T cell counts between 100-200 cells/ μ L. The results showed that the risk ratio of CrAg positivity prevalence among HIV-infected persons with CD4+ T cell counts <100 cells/ μ L was 1.82 times that of those with 100-200 cells/ μ L (95%CI: 0.77-4.30; $p=0.007$, $I^2=63\%$; three studies; 1886 persons). The risk ratio of the incidence of CM among HIV-infected persons with CD4+ T cell counts <100 cells/ μ L was 2.53 times that of those with CD4+ T cell counts between 100-200 cells/ μ L (95%CI: 0.50-12.71, $p=0.26$, $I^2=59\%$; four studies, 1960 persons). The risk ratio of the all-cause mortality among HIV-infected persons with CD4+ T cell counts <100 cells/ μ L was 4.15 times that of those with CD4+ T cell counts between 100-200 cells/ μ L (95%CI: 0.89-19.42, $p=0.07$, $I^2=0\%$; two studies, 1552 persons). Further, the risk ratio of the incidence of CM among persons with CD4+ T cell counts between 100-200 cells/ μ L receiving placebo or no intervention was 1.15 times compared to those receiving antifungal treatment (95%CI: 0.16-8.13, $p=0.97$, $I^2=0\%$; three studies; 140 persons). The risk ratio of the all-cause mortality among persons with CD4+ T cell counts between 100-200 cells/ μ L receiving antifungal treatment was 0.27 compared to those receiving placebo or no intervention (95%CI: 0.01-4.93, p and I^2 not applicable; one study; seven persons). Details are shown in Table 3.

Discussion

Several meta-analyses have been conducted in the past designed to evaluate the necessity of CrAg screening and administration of pre-emptive antifungal treatment among HIV-infected CrAg+ persons with varying low CD4 levels. For example, Temfack *et al* investigated the effectiveness of CrAg detection and the initiation of pre-emptive fluconazole treatment in HIV-infected persons with cryptococcal antigenemia and CD4+ T cell levels <100 cells/ μ L (16). Their results suggested that administration of fluconazole pre-emptive therapy to CrAg+ persons greatly reduced the risk of incident CM, and may have specific survival benefits (16). Another meta-analysis conducted by Ssekitooleko *et al* also suggested that in resource-limited settings, CrAg+ persons should routinely receive primary antifungal prophylaxis (18), but they failed to clarify at which specific CD4+ T cell count antifungal prophylaxis should be initiated. Ford *et al*'s (19) meta-analysis only reported the combined prevalence of cryptococcal antigenemia among HIV-infected persons with CD4+ T cell counts \leq 100 cells/ μ L, and with CD4+ T cell counts between 101~200 cells/ μ L. Importantly, their study did not mention whether pre-emptive antifungal treatment was necessary or effective among HIV-infected persons with cryptococcal antigenemia at these two CD4+ T cell count strata. From the above studies, it may be gathered that the prudence and benefits of CrAg screening and pre-emptive antifungal therapy remain unclear at higher CD4+ T cell counts. The objective of our meta-analysis was to investigate the prevalence of cryptococcal antigenemia in HIV-infected patients with CD4+ T cell counts <200 cells/ μ L, and the potential benefit of pre-emptive antifungal therapy among HIV-infected persons with cryptococcal antigenemia and CD4+ T cell counts <200 cells/ μ L.

The pooled prevalence of CrAg positivity in HIV-infected persons with CD4+ T cell counts <200 cells/ μ L was 6% (14 studies) in our meta-analysis, which was similar to 6% (31 studies) among HIV-infected persons with CD4+ T cell counts <100 cells/ μ L in Temfack's meta-analysis (16) and 6.5% (60 studies) among HIV-infected persons with CD4+ T cell counts <100 cells/ μ L in Ford's meta-analysis (19). Our results showed that the incidence of CM in CrAg+ persons was significantly higher than that of in CrAg- persons with CD4+ T cell counts <200 cells/ μ L, even though the all-cause mortality in CrAg+ persons was similar to that of CrAg- persons. While in Temfack's study, the incidence of CM was 21.4% among CrAg+ persons and 0.4% in CrAg- persons, and the all-cause mortality among CrAg+ persons was significantly higher than in CrAg- persons (39.7% vs 13.9%, respectively) (16). From the above results, it is clear that regardless of whether the CD4+ T cell count is <200 or <100 cells/ μ L, the incidence of CM is higher in CrAg+ persons than in CrAg- persons. Therefore, antifungal prophylaxis seems imperative for HIV-infected persons with cryptococcal antigenemia who have CD4+ T cell counts <200 cells/ μ L.

Our results have demonstrated that, in persons with CD4+ T cell count <200 cells/ μ L, the risk ratio of CM events among those who received placebo or no intervention was significant higher than those who received antifungal therapy, suggesting that antifungal prophylaxis significantly reduce the risk of CM events in CrAg+ persons with a higher CD4+ T-cell counts. However, the very limited data among persons with CD4+ T cell counts between 101~200 cells/ μ L restricted our capacity to investigate it further. Thus, more specific data are needed to demonstrate the benefit of antifungal treatment in HIV-infected persons with CD4+ T cell counts between 100-200 cells/ μ L, and warrants further investigation.

No significant difference in all-cause mortality was found in our meta-analysis among CrAg+ persons who received pre-emptive antifungal therapy versus placebo or no intervention. This is a somewhat surprising outcome, and the reason of this may be associated with the discrepant sample sizes in these two groups (636 vs. 1259).

We considered the following possible reasons for clinical and methodological heterogeneity: discrepancies in follow-up time for reporting CM events and death events, variations in drug dosing, regimens, or drug class of prescribed antifungal therapy, ART status of subjects, and risk of bias. For example, the study durations ranged from one year to six years, and the dosing of azole antifungal treatments ranged from 100 mg/d to 900 mg/d. With regards to reporting bias, it is possible that the unformed funnel plot for all-cause mortality could be a consequence of the varied ART status of study participants, different dosage regimens and duration of treatment and the different follow-up periods in each of the individual studies.

There are some limitations in our study. Firstly, the data supporting the association between prevalence of CrAg positivity and occurrence of adverse outcomes in HIV-infected persons with CD4+ T-cell counts between 100-200 cells/ μ L is sparse. Secondly, there exists a paucity of new data regarding CrAg positivity prevalence, CM incidence, and all-cause mortality in HIV-infected persons with CD4+ T-cell counts <200 cells/ μ L since 2015 (35), and our pooled

outcome analyses relied heavily on older studies, which may be less applicable to the modern test-and-treat era. And thirdly, the dosage and durations of azole therapy was not assessed in our meta-analysis. The preceding limitations may contribute to the clinical and methodological heterogeneity in our study.

Conclusions

In our meta-analysis, the incidence of CM in CrAg+ persons were significantly higher than in CrAg- persons with CD4+ T cell counts<200 cells/ μ L. Furthermore, the incidence of CM was significantly reduced by pre-emptive antifungal therapy in CrAg+ persons with CD4+ T cell counts<200 cells/ μ L. Nevertheless, more specific intervention data are needed in persons with CD4+ T cell counts between 101~200 cells/ μ L to better clarify the benefit of CrAg screening and pre-emptive antifungal treating in CrAg- persons with CD4+ T cell counts<200 cells/ μ L more clear.

Declarations

- Ethics approval and consent to participate

Not applicable.

- Consent to publication

Not applicable.

- Availability of data and materials

All the data and materials are available from Pubmed, Cochrane Library, MEDLINE/EMBASE and Web of Science.

- Competing interests

All authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.

- Funding

This work was supported by the National Science and Technology Major Project of China during the 13th Five-year Plan Period (2018ZX10302104, 2017ZX10201101), key project of joint medical research project of science and health in Chongqing in 2019 (2019ZDXM012), Major Project of Beijing Municipal Science and Technology Committee (D161100000416003, D171100000517003).

- Authors' Contributions

YL, XJH, HW, XFY and YKC conceived and designed the study. YL, YYQ, JHH and AXL identified studies to be screened. XJH and HC identified studies for eligibility, extracted data, and assessed the methodological quality of included studies. YL performed the data analysis with assistance from XJH, and YKC. All authors read and approved the final manuscript.

- Acknowledgements

Thanks to all authors for their contributions to this manuscript. We wish to thank Vijay Harypursat of Chongqing Public Health Medical Center for his help in language improvement to this manuscript.

References

1. Govender NP, Roy M, Mendes JF, Zulu TG, Chiller TM and Karstaedt AS. Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. *HIV Med.* 2015;16(8):468-76.
2. Longley N, Jarvis JN, Meintjes G, Boule A, Cross A, Kelly N, et al. Cryptococcal Antigen Screening in persons Initiating ART in South Africa: A Prospective Cohort Study. *Clin Infect Dis.* 2016;62(5):581-587.
3. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *Lancet Infect Dis.* 2017;17(8):873-881.
4. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. *AIDS.* 2002;16(7): 1031-8.
5. Larson BA, Rockers PC, Bonawitz R, Srirottan C, Glencross DK, Cassim N, et al. Screening HIV-Infected persons with Low CD4 Counts for Cryptococcal Antigenemia prior to Initiation of Antiretroviral Therapy: Cost Effectiveness of Alternative Screening Strategies in South Africa. *PLoS One.* 2016;11(7):e0158986.
6. AwotiwonAA, Johnson S, Rutherford GW, Meintjes G, Eshun-Wilson I. Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people. *Cochrane Database Syst Rev.* 2018;2018(8): CD004773.
7. Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison TS. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. *BMC Infect Dis.* 2010;10:67.

8. Sathyanarayanan V, Razak A, Chakraborty J. Clinical profile of disseminated cryptococcal infection – a case series. *Asian Pacific Trop Med.* 2010;3:818–20
9. Kaplan JE, Vallabhaneni S, Smith RM, Chideya-chihota S, Chehab J and Park B. Cryptococcal antigen screening and early antifungal treatment to prevent cryptococcal meningitis: a review of the literature. *JAIDS.* 2015;68(Suppl 3):331-339.
10. Beyene T, Woldeamanuel Y, Asrat D, Ayana G, Boulware DR. Comparison of Cryptococcal Antigenemia between Antiretroviral Naïve and Antiretroviral Experienced HIV Positive persons at Two Hospitals in Ethiopia. *PLoS One.* 2013;8(10):e75585.
11. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R and Harrison TS. Screening for cryptococcal antigenemia in persons accessing an antiretroviral treatment program in South Africa. *Clin Infect Dis.* 2009;48(7):856-62.
12. Meya D, Rajasingham R, Nalintya E, Tenforde M, Jarvis JN. Preventing Cryptococcosis Shifting the Paradigm in the Era of Highly Active Antiretroviral Therapy. *Curr Trop Med Rep.* 2015;2(2): 81-9.
13. World Health Organization. Guidelines for the diagnosis, prevention and management of Cryptococcal disease in HIV-infected adults, adolescents and children. 2018.<http://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/>. Assessed March 2018.
14. The Joanna Briggs Institute. Joanna Briggs Institute Reviewers' Manual: 2016 edition. Australia: The Joanna Briggs Institute; 2016.
15. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* 2011;343:d5928.
16. Temfack E, Bigna JJ, Luma HN, Spijker R, Meintjes G, Jarvis JN, et al. Impact of routine cryptococcal antigen screening and targeted pre-emptive fluconazole therapy in antiretroviral naive HIV-infected adults with less than 100 CD4 cells/ μ L: a systematic review and meta-analysis. *Clin Infect Dis.* 2018;doi: 10.1093/cid/ciy567
17. Huang Y, Huang X, Luo Y, Zhou Y, Tao X, Chen H, et al. Assessing the Efficacy of Lopinavir/Ritonavir-Based Preferred and Alternative Second-Line Regimens in HIV-Infected persons: A Meta-Analysis of Key Evidence to Support WHO Recommendations. *Front Pharmacol.* 2018;9:890.
18. Ssekitooleko R, Kanya MR, Reingold AL. Primary prophylaxis for cryptococcal meningitis and impact on mortality in HIV: a systematic review and meta-analysis. *Future Virol.* 2013;8(9).
19. Ford N, Shubber Z, Jarvis JN, Chiller T, Greene G, Migone C, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. *Clin Infect Dis.* 2018;66(suppl_2):S152-S159.
20. Chariyalertsak S, Supparatpinyo K, Sirisanthana T and Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in persons with advanced human immunodeficiency virus infection in Thailand. *Clin Infect Dis.* 2002;34(2):277-84.
21. Manfredi R, Mastroianni A, Coronado OV and Chiodo F. Fluconazole as prophylaxis against fungal infection in persons with advanced HIV infection. *Arch Intern Med.* 1997;157(1):64-9. PMID: 8996042
22. Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke D, Whitworth J, Coutinho A, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. *Lancet Infect Dis.* 2011;11:933–41.
23. McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black JR, Bamberger DM, et al. Itraconazole prophylaxis for fungal infections in persons with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *Clin Infect Dis.* 1999;28(5):1049-56.
24. Chetchotisakd P, Sungkanuparph S, Thinkhamrop B, Moosikapun P and Boonyaprawit P. A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected persons with severe immune deficiency. *HIV Med.* 2004;5(3):140-3.
25. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count \leq 100 cells/ μ L who start HIV therapy in resource-limited settings. *Clin Infect Dis.* 2010;51: 448-55.
26. Kapoor SW, Magambo KA, Kalluvya SE, Fitzgerald DW, Peck RN, Downs JA. Six-month outcomes of HIV-infected persons given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. *AIDS.* 2015; 29(18):2473-8.
27. Vallabhaneni S, Longley N, Smith M, Smith R, Osler M, Kelly N, et al. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa. *J Acquir Immune Defic Syndr.* 2016;72(2):e37-e42.
28. Rick F, Niyibizi AA, Shroufi A, Onami K, Steele SJ, Kuleile M, et al. Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho. *PLoS One.* 2017;12(9):e0183656.
29. Kwan CK, Leelawiwat W, Intalaporn P, Anekthananon T, Raengsakulrach B, Peters PJ, et al. Utility of Cryptococcal Antigen Screening and Evolution of Asymptomatic Cryptococcal Antigenemia among HIV-Infected Women Starting Antiretroviral Therapy in Thailand. *J Int Assoc Provid AIDS Care.* 2014;13(5):434-7.
30. Ganiem AR, Indrati AR, Wisaksana R, Meijerink H, van der Ven A, Alisjahbana B, et al. Asymptomatic cryptococcal antigenemia is associated with mortality among HIV-positive persons in Indonesia. *J Int AIDS Soc.* 2014;17:18821.
31. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. *Trop Med Int Health.* 2007;12(8):929-35.
32. Linares L, Paz J and Bustamante B. Cryptococcal antigenemia in HIV-infected persons with a CD4 count \leq 100 cell mm^{-3} . *Mycoses Vol.* 2012;55: 206-207.
33. Meya DB, Kiragga AN, Nalintya E, Morawski BM, Rajasingham R, Park BJ, et al. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 $<$ 100 Cells/ μ L: A Stepped-Wedge, Cluster-Randomized Trial. *J Acquir Immune Defic Syndr.* 2019;80(2):182-189.

34. Borges MASB, de Araújo Filho JA, Oliveira BJS, Moreira IS, de Paula VV, de Bastos AL, et al. Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil. PLoS One. 2019;14(7):e0219928.
35. 35. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization.2015.
<http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en>Assessed September 2015.

Tables

Table 1. Characteristics of the 17 included studies.

Study ID	Number of participants	Study type	Study duration	Age (years)	CD4 (cells/ μ L)	CrAg screening methods	CM diagnostic methods	Location	Therapeutic regimens	Primary outcomes	
										Incidence of CM	All-cause mortality
tsak,	129	Prospective study	104 weeks	18~60	≥ 200	Not report	Fungal culture, a histopathological examination, or buffy coat smear	Thailand	63 for oral itraconazole (200 mg/day) as group 1; 66 for matched placebo as group 2	0 in group 1; 7 in group 2	12 in group 1; 12 in group 2
	249	Retrospective study	6 years	22~59	≥ 200	Not report	Specific polysaccharide antigen detection from body fluids	Italy	128 for oral fluconazole (100 mg/d every third week) as group 1; 121 for no antifungal treatment as group 2	2 in group 1; 9 in group 2	12 in group 1; 12 in group 2
	1519	Prospective study	42 months	Not report	≥ 200	Not report	CrAg titre > 1:8 on two occasions, or a positive CSF CrAg or Cryptococcus neoformans grown from blood or CSF culture	Uganda	760 fluconazole 200 mg 3 times per week for minimum 12 weeks as group 1; 759 allocated to placebo as group 2	1 in group 1; 18 in group 2	0 in group 1; 0 in group 2
	295	Randomized, placebo-Controlled study	Not report	≥ 13	≥ 150	Not report	Fungal culture	Not report	149 for itraconazole capsules (200 mg/day) as group 1; 146 for matched placebo as group 2	1 in group 1; 8 in group 2	32 in group 1; 32 in group 2
sakd,	90	Prospective study	18 months	>14	≥ 100	Not report	Not report	Thailand	3 received fluconazole (400 mg weekly) as group 1; 7 received placebo as group 2	3 in group 1; 7 in group 2	2 in group 1; 2 in group 2
0	584	Prospective study	30 months	≥ 18	≥ 200	Not report	Not report	Uganda	Fluconazole (200~400 mg) for 2~4 weeks	3 in CrAg+ persons and 0 in CrAg- persons	6 in CrAg+ persons and 0 in CrAg- persons
015	72	Retrospective study	15 months	≥ 18	≥ 200	LFA	Positive CSF India ink	Sub-Saharan Africa	800 mg fluconazole orally for 2 weeks, followed by 400 mg orally for 2 weeks	0 in CrAg+ persons and 1 in CrAg- persons	2 in CrAg+ persons and 8 in CrAg- persons
	1079	Retrospective study	19 months	Not report	< 200	LA or the Latex-Cryptococcus antigen detection system	CrAg detected in CSF	South Africa	Fluconazole ranging from 400 to 800 mg per day for at least 3 months	unknow in persons with CD4 < 200	unknow in persons with CD4 < 200
017	783	Prospective study	18 months	>14	≤ 150	LFA	CSF CrAg	Ethiopia	Fluconazole 800 mg/day 2 weeks, followed by 400 mg/day 8 weeks	2 in CrAg+ persons and 0 in CrAg- persons	4 in CrAg+ persons and 0 in CrAg- persons
eni,	1159	Retrospective study	1 year	≥ 18	≥ 100	LA	Laboratory-confirmed	South Africa	Fluconazole (any dose and any duration)	0 in CrAg+ persons and 9 in CrAg- persons	No in CrAg+ persons and No in CrAg- persons
r,	128	Observational study	1 year	Not report	≥ 100	LFA	Lumbar puncture and CSF testing using the CrAg LFA	Lesotho	Fluconazole for 10 weeks	2 in CrAg+ persons and No in CrAg- persons	3 in CrAg+ persons and No in CrAg- persons
4	84	Observational study	48 weeks	31 (median)	<100	LA	India ink stain of CSF	Thailand	Fluconazole 400 mg taken orally weekly	2 in CrAg+ persons and 0 in CrAg- persons	0 in CrAg+ persons and 4 in CrAg- persons
016	638	Prospective study	3 years	>18	≤ 100	LFA and LA	CSF CrAg-LFA	South Africa	Fluconazole 800 mg/day for 2 weeks, 400 mg/day for 8 weeks, and 200 mg daily thereafter	4 in CrAg+ persons and 2 in CrAg- persons	7 in CrAg+ persons and 71 in CrAg- persons
014	810	Prospective study	4 years	Not report	≥ 100	Semiquantitative LFA	Cryptococcus found in CSF, either with direct India ink staining or positive CrAg in CSF	Indonesia	Fluconazole administered part persons: 18 in 30 CrAg+ persons and 102 in 294 CrAg- persons	6 in CrAg+ persons and 0 in CrAg- persons	18 in CrAg+ persons and 0 in CrAg- persons
09	315	Retrospective study	1 year	34 (mean)	19~77	LA	Microbiologically confirmed	South Africa	No intervention	6 in CrAg+ persons and 0 in CrAg- persons	9 in CrAg+ persons and 38 in CrAg- persons
007	377	Retrospective study	18 months	≥ 18	≤ 100	LA	Not report	Uganda	No intervention	3 in CrAg+ persons and 4 in CrAg- persons	5 in CrAg+ persons and 19 in CrAg- persons
012	365	Retrospective study	12 months	Not report	≤ 100	LFA	Not report	Peruvian, Latin-America	No intervention	3 in CrAg+ persons and 0 in CrAg- persons	0 in CrAg+ persons and 0 in CrAg- persons
9	2108	Prospective study	18 months	≥ 14	<100	LFA	CSF CrAg	Uganda	Fluconazole 800 mg daily for 2 weeks followed by 400 mg daily for 8 weeks	12 in CrAg+ persons with antifungal treatment and 3 in CrAg- persons	31 in CrAg+ persons with antifungal treatment and 3 in CrAg- persons
019	214	Prospective study	36 months	>17	<200	LFA	India ink	Brazil	Fluconazole 900	1 in CrAg+ persons	2 in CrAg+ persons

microscopy on the CSF, CSF CrAg test and fungal culture

mg for 2 weeks, 450 mg for 8 to 10 weeks and a subsequent maintenance dose of 150-300 mg with antifungal treatment and 0 in CrAg+ persons without intervention

“No” means “no data”; “Yes” means “data exists”; OIs means: other opportunity infections.

*: “Govender, 2015” study was included for evaluating the prevalence of CrAg positivity. Only the data in persons with CD4<200 was used. “LFA”: lateral flow assay; “LA”: Latex Agglutination; LP: lumbar puncture

Table 2. The incidence of CM and all-cause mortality among CrAg+ and CrAg- persons, and among persons with and without antifungal therapy.

Incidence of CM among CrAg+ and CrAg- persons	Number of reported studies	Number of persons	ES (95%CI)	I ²	p
1.1 Incidence of CM among CrAg+ persons	14	2366	0.07 (0.04, 0.10)	72.8%	0.000
1.2 Incidence of CM among CrAg- persons	5	4074	0.00 (0.00, 0.01)	53.6%	0.071
Incidence of CM among persons with and without antifungal therapy	Number of reported studies	Number of persons	ES (95%CI)	I ²	p
2.1 Incidence of CM among persons with antifungal therapy	11	1328	0.03(0.01, 0.05)	70.5%	0.000
2.2 Incidence of CM among persons without antifungal therapy	9	1252	0.09 (0.05, 0.13)	73.7%	0.000
All-cause mortality in CrAg+ and CrAg-persons	Number of reported studies	Number of persons	ES (95%CI)	I ²	p
1.1 All-cause mortality among CrAg+ persons	14	2520	0.18 (0.11, 0.25)	93.6%	0.000
1.2 All-cause mortality among CrAg- persons	7	4054	0.17 (0.07, 0.27)	98.8%	0.000
All-cause mortality among persons who with and without antifungal therapy	Number of reported studies	Number of persons	ES (95%CI)	I ²	p
2.1 All-cause mortality among persons with antifungal therapy	10	636	0.17 (0.11, 0.22)	69.5%	0.000
2.2 All-cause mortality among persons without antifungal therapy	7	1202	0.16 (0.07, 0.24)	92.4%	0.000

Table 3. Comparisons of CrAg positivity, incidence of CM and all-cause mortality among HIV-infected persons stratified by CD4+ T cell count

Year	Prevalence of CrAg positivity		Incidence of CM				All-cause mortality			
	CD4 >100 (cells/ µL)	CD4 100~200 (cells/µL)	CD4 >100 (cells/µL)		CD4 100~200 (cells/µL)		CD4 >100 (cells/µL)		CD4 100~200 (cells/µL)	
			with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment
2008	Not reported		0 of 40	6 of 45	0 of 23	0 of 21	Not reported		Not reported	
2009	Not reported		17 of 698		2 of 821		3* of 698		0* of 821	
2010	Not reported		0 of 101	7 of 103	1 of 48	1 of 43	Not reported		Not reported	
2011	26 of 295	7 of 298	3 of 21	2 of 5	Not reported		6 of 21	5 of 5	0 of 4	1 of 3
2012	20 of 708	6 of 371	Not reported		Not reported		Not reported		Not reported	
2013	12 of 159	5 of 5	0 of 9	0 of 3	0 of 1	1 of 4	Not reported		Not reported	
Overall	Pooled CrAg+ prevalence: 0.06 [-0.02, 0.11], $p=0.001$, $I^2=86.5\%$	Pooled CrAg+ prevalence: 0.02 [0.01, 0.03], $p=0.146$, $I^2=48\%$	Risk ratio with 95%CI: 7.67 [2.03, 29.05], $p=0.36$, $I^2=1\%$		Risk ratio with 95%CI: 1.15 [0.16, 8.13], $p=0.97$, $I^2=0\%$		Risk ratio with 95%CI: 0.32 [0.16, 0.64], p and I^2 not applicable		Risk ratio with 95%CI: 0.27 [0.01, 4.93], p and I^2 not applicable	
with	1.82 [0.77, 4.30], $p=0.007$, $I^2=63\%$		2.53 [0.50, 12.71], $p=0.26$, $I^2=59\%$				4.15 [0.89, 19.42], $p=0.07$, $I^2=0\%$			

*: Died within four weeks

Figures




Figure 1

Flow chart of the study selection process




Figure 2

Prevalence of CrAg positivity among HIV-infected persons with CD4+ T cells < 200 cells/μL. Abbreviations: ES=effect size.




Figure 3

Forest plots of incidence of CM among CrAg + persons receiving azole vs. no intervention or placebo. Abbreviations: M-H, Mantel Haenszel; CI, confidence interval. ("Azole inter" means "Azole drug intervention", "No inter or plac" mean "No intervention or placebo").




Figure 4

Forest plots of all-cause mortality among CrAg + persons receiving azole vs. no intervention or placebo. Abbreviations: M-H, Mantel Haenszel; CI, confidence interval. ("Azole inter" means "Azole drug intervention", "No inter or plac" mean "No intervention or placebo").

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [3RevisedSupplementaryMaterial.doc](#)